


Genome-wide association studies

Dr. Martina Müller-Nurasyid

IMBEI, Genomische Statistik und Bioinformatik Universitätsmedizin Mainz 01.06.2022




From DNA to function Feasibility of identifying genetic effects




TA Manolio *et al. Nature* **461**, 747-753 (2009)












Genetic data Types of variants

Reference sequence









Genetic data Coding genotypes for analysis

coding for analysis











Genetic heterogeneity





Genetic heterogeneity - example

ADMIXTURE plot for Kuwait study sample





Imputation

Study sample

....A.....A....A....

Reference haplotypes



Study sample

cgagAtctcccgAcctcAtgg cgaaGctcttttCtttcAtgg

Reference haplotypes



Imputationservers


TOPMED Imputation Server https://imputation.biodatacatalyst.nhlbi.nih.gov

Michigan Imputation Server https://imputationserver.sph.umich.edu

Sanger Imputation Server https://imputation.sanger.ac.uk

Various reference panels are available...








Genome-wide association study (GWAS)

- Choose a simple analysis model
- Run your model for each single variant
- Extract results for each variant
- Plot p-values

Genome-wide significance level

- Assume α<0.05 is considered as significance level
- Probability for at least one false positive result in two independent tests: $1-(1-\alpha)^2 = 1-(1-0.05)^2 = 1-0.95^2 = 0.0975$
- Error probability for N independent tests: 1-(1-α)^N
- Simplification: $(1 \alpha)^N \approx 1 N \cdot \alpha$
 - $\rightarrow \alpha_{bonf} = \alpha/N$ is the Bonferroni corrected significance level









Genomewide Association Study of Severe Covid-19 with Respiratory Failure, NEJM 06/2020 (Ellinghaus et al)

Manhattan plot










http://locuszoom.org



LocusZoom is a suite of tools to provide fast visualization of GWAS results for research and publication.

Original LocusZoom (R/Python) is ideal for batch generation of static plots.

LocusZoom.js (JavaScript) aims to make LocusZoom plots interactive and scriptable.

Interactive Plots with LocusZoom.js



MY.LOCUSZOOM.ORG
UPLOAD, ANALYZE, AND SHARE



LOCALZOOM

EXPLORE WITHOUT UPLOADING

Legacy Services (not actively maintained)


SINGLE PLOT
YOUR DATA - ORIGINAL LOCUSZOOM

BATCH PLOT WITH HITSPEC
YOUR DATA - ORIGINAL LOCUSZOOM


INTERACTIVE PLOT
PUBLISHED GWAS - LOCUSZOOM.JS




Genomewide Association Study of Severe Covid-19 with Respiratory Failure, NEJM 06/2020 (Ellinghaus et al)













Original DNA strand

DNA	ACG	GGT	ATA	CGA
RNA	UGC	CCA	UAU	GCU
Amino acid	Cys	Pro	Tyr	Ala

Substitution

ACA	GGT	ATA	CGA
UGU	CCA	UAU	GCU
Cys	Pro	Tyr	Ala

Synonymous change



Original DNA strand

DNA	ACG	GGT	ATA	CGA
RNA	UGC	CCA	UAU	GCU
Amino acid	Cys	Pro	Tyr	Ala

Substitution

ACC	GGT	ATA	CGA
UGG	CCA	UAU	GCU
Trp	Pro	Tyr	Ala

Nonsynonymous change



Original DNA strand


DNA	ACG	GGT	ATA	CGA
RNA	UGC	CCA	UAU	GCU
Amino acid	Cys	Pro	Tyr	Ala

Substitution

ACT	GGT	ATA	CGA
UGA	CCA	UAU	GCU
stop			•••










Variant annotation SNIPA







SNiPA - a tool for annotating and browsing genetic variants

Welcome to SNiPA!

HelmholtzZentrum münchen German Research Center for Environmental Health

SNiPA offers both functional annotations and linkage disequilibrium information for bi-allelic genomic variants (SNPs and SNVs). SNiPA combines LD data based on the 1000 Genomes Project with various annotation layers, such as gene annotations, phenotypic trait associations, and expression-/metabolic quantitative trait loci. See the documentation for all data sources integrated into SNiPA. For information on updates and new releases, see the Release Notes.



Find variants that are linked to other variants by LD.

See how to use SNIPA and its interactive features.

Proxy Search

Documentation





Block Annotation
Summarize variant annotations within LD blocks or

Å	Linkage Disequilibrium Plot Combine LD data and annotations in an interactive plot



Current release

SNiPA v3.4 (released November 13th, 2020)


Genome assembly: GRCh37.p13 Ensembl version: 87 1000 genomes: phase 3 version 5

SNiPA now incorporates **two recent mQTL studies** by Schlosser et al. (Nature Genetics, Feb 2020) and Lotta et al. (preprint, Jul 2020), as well as **pQTLs** in the context of SARS-CoV-2 from Pietzner et al. (preprint, Jul 2020). Additionally, over 4 million unique pooled and sex-specific associations from the Neale lab UK Biobank GWASs were integrated. Further updates include the most recent versions of **GTEx** for eQTL data as well as the **GWAS Catalog**, HGMD public and ClinVar, totalling to more than 940,000 genetic trait associations.

For further information, see the release notes or the documentation.



Variant annotation SNIPA



Last update 11/2020: https://snipa.helmholtz-muenchen.de/snipa3/



From DNA to function Public resources: GWAS Catalog



Studies with available summary statistics

Users can access all summary statistics from the Catalog FTP site, which is updated nightly following submission. They can also be accessed in the tables below (separate tables for the published and unpublished summary statistics). Metadata associated with summary statistics can be downloaded from Downloads.

If you are an author and have summary statistics you would like to submit to the GWAS Catalog please visit our submission page. These data are made available either through CC0 or EMBL-EBI's standard terms of use, more details can be found here. For licensing information of individual studies, please reveal "Usage License" column.


For information on summary statistics and the summary statistics REST API please read the documentation

List of published studies with summary statistics

Data from ~30,300 published and ~5,800 pre-/unpublished studies http://www.ebi.ac.uk/gwas/downloads/summary-statistics




From DNA to function Public resources: GENEBASS (UK Biobank)






Running a GWAS... extensions....





Running a GWAS... extensions...





Genetic variation Population stratification

Example: chop-stick study Molecular Psychiatry (2000)












Genetic variation Population stratification



Overall blue: 14/20 vs. 12/20 Population 1: 10/12 vs. 7/8 Population 2: 4/8 vs. 8/15

Balding, Nature Reviews Genetics 2006



Genetic variation Population stratification

The problem of population stratification plays a role when:

- the study sample consists of two subpopulations
- which are disproportionally represented in cases and controls
- allele frequencies vary between the two subpopulations




Genetic variation Reasons for population stratification

- Populations with different ancestry
- Hidden family structures
- Higher penetrance of the causal allele in the subgroup because of a different environment (e.g. diet)
- Ascertainment bias
 (e.g. the subgroup is more closely monitored by health services than the
 general population, so that cases from the subgroup are more likely to
 be included in the study)
- Different genotyping platforms/chips/runs for cases and controls that result in different genotype quality




Check for population stratification







Genomewide Association Study of Severe Covid-19 with Respiratory Failure, NEJM 06/2020 (Ellinghaus et al)














Meta-analysis in GWAS



From covid19hg website: https://www.covid19hg.org/data-sharing/



Meta-analysis in GWAS


Common methods for pooling estimates

- z-scores weighted by study size
 - only p-values and sample size are required
 - > no pooled estimates are available
- inverse variance weighting
 - effect estimates and standard errors for each study needed
 - pooled estimates are available



Genomewide Association Study of Severe Covid-19 with Respiratory Failure, NEJM 06/2020 (Ellinghaus et al)

Manhattan plot




total (Italy/Spain)	2090/1725		
cases	835/775		
controls	1255/950		



COVID-19 Host Genetics Initiative, Release 6 (06/2021)

susceptibility




Total	2,586,691
Cases	112,612
Controls	2 474,079





Mapping the human genetic architecture of COVID-19, Nature 07/2021 (COVID-19 Host Genetics Initiative)





Measures of genetic heterogeneity in meta-analyses

 I^2 = percentage of the total variation across studies due to heterogeneity beyond chance

*I*² is based in Cochran's Q (weighted sum of the squared derivation between study and meta-analysis effect estimates)

 $l^2>50\%$ is generally considered to indicate heterogeneity between studies

Test statistics are available



Meta-analysis in GWAS


Fixed-effect metaanalysis assume that in all studies, generally, the same effect is present. Effect estimation varies around this true effect.

Random effect metaanalysis allows effects to vary between studies although a general effect can be described. This should generally be applied, in case heterogeneity between study-specific effect is strong.



Measuring genetic heterogeneity in meta-analyses

IL6 gene promoter polymorphism and type 2 diabetes



Effects of genetic heterogeneity in meta-analyses

— FTO PPARG	rs9300039 rs8050136	Q (df) ^a [p] 8.38 (3) [0.039] 12.98 (4) [0.011]	I ² (95% CI) 64% (0–86)	Random effects OR (95% CI) 1.29 (1.11–1.50)	Fixed effects OR (95% CI) 1.26 (1.15–1.37)	Random effects p-value	Fixed effects p-value
FTO PPARG	rs8050136			1.29 (1.11–1.50)	1 26 (1 15–1 37)	0.001	0
PPARG		12.98 (4) [0.011]	500/ (0.05)		1.20 (1.15 1.57)	0.001	2.8×10^{-8}
	rs1801282		69% (0–86)	1.15 (1.06–1.25)	1.17 (1.12–1.23)	0.001	2.5×10 ⁻¹²
		6.93 (4) [0.14)	42% (0–76)	1.14 (1.06–1.23)	1.13 (1.08–1.20)	0.0007	3.4×10^{-6}
CDKAL1	rs10946398	8.76 (5) [0.12]	43% (0–76)	1.13 (1.07–1.18)	1.12 (1.08–1.15)	1.2×10 ⁻⁶	1.9×10 ⁻¹⁰
SLC30A8	rs13266634	3.17 (5) [0.67]	0 (0–61)	1.13 (1.08–1.17)	1.13 (1.08–1.17)	4.1×10 ⁻⁹	4.1×10 ⁻⁹
CDKN2B	rs564398	3.62 (4) [0.46]	0% (0-64)	1.11 (1.06–1.15)	1.11 (1.06–1.15)	5.8×10 ⁻⁷	5.8×10 ⁻⁷
	rs5015480- rs1111875	6.20 (5) [0.29]	19% (0–68)	1.13 (1.08–1.17)	1.12 (1.08–1.17)	2.2×10 ⁻⁸	3.2×10 ⁻¹⁰
KCNJ11	rs5215	3.50 (4) [0.48]	0% (0-64)	1.14 (1.09–1.18)	1.14 (1.09–1.18)	9×10 ⁻¹¹	9×10^{-11}
IGF2BP2	rs4402960	7.08 (5) [0.21]	29% (0–71)	1.15 (1.10–1.20)	1.15 (1.11–1.19)	2.9×10 ⁻¹⁰	1.1×10^{-15}
CDKN2B	rs10811661	4.15 (5) [0.53]	0% (0-61)	1.20 (1.15–1.25)	1.20 (1.15–1.25)	2.7×10^{-15}	2.7×10^{-15}
TCF7L2	rs7901695	1.31 (4) [0.86]	0% (0-64)	1.37 (1.32–1.43)	1.37 (1.32–1.43)	1.0×10 ⁻⁴⁸	1.0×10 ⁻⁴⁸


CI: confidence interval; OR: odds ratio

^adf = degrees of freedom; not all markers were tested by all 3 investigations in their replication efforts, thus even with splitting the discovery and replication phases, there are fewer than 6 datasets (df = 5) for some variants.



Effects of genetic heterogeneity in meta-analyses

Forrest plot for *FTO* variant




Ioannidis, PLoS ONE 2007




Causes for heterogeneity in meta-analyses

- The identified variant is in LD with the true causative variant, while LD can vary across populations
- The true association can be with a **correlated phenotype**, while the correlation between phenotypes can vary across populations
- Association results may be biased, e.g. due to population stratification, genotyping error, phenotype misclassification...
- The true effect results from gene-gene or gene-environment interactions
- "Winner's curse": initiation of the meta-analysis through single study with overwhelming results












Polygenic risk scores for risk stratification Example: QT interval




Allelic score of 12 QT-prolonging variants in N=10,563 study participants


- \triangleright Effect per QT prolonging allele = 1.53ms \pm 0.08ms (p=1.79*10⁻⁸⁸)
- > Several analysis of low vs. high QT score showed strong association to QT



Application example: https://www.cardioscore.eu/




Cumulative absolute risk of developing Coronary Artery Disease (CAD) in UK Biobank population stratified by different percentiles of the Polygenic Risk Score (PRS)



Prevalence gradient for Coronary Artery Disease (CAD) across the distribution of the Polygenic Risk Score in UK Biobank population. Each point represents a different percentile of the PRS distribution



https://www.pgscatalog.org/





Vielen Dank für Ihre Aufmerksamkeit!

Kontakt:

Dr. Martina Müller-Nurasyid

Senior Scientist

IMBEI, Genomische Statistik und Bioinformatik

Universitätsmedizin Mainz

Langenbeckstraße 1, 55131 Mainz

Tel. +49 6131 39 - 38719

E-Mail: martimue@uni-mainz.de

www.unimedizin-mainz.de

